Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
04 déc. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...
FDA approves muscular dystrophy drug built on Children’s National research
27 oct. 2023 09h27 HE
|
Children's National Hospital
WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
26 oct. 2023 15h19 HE
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
16 oct. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that...
Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho, FibroGen, Sarepta, Capricor, Daiichi Sankyo, Solid Biosciences
27 sept. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho,...
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
09 août 2023 16h17 HE
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
24 juil. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
30 mai 2023 05h00 HE
|
AKAMPION
FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)DMD is a designated orphan disease in both Europe and the...
Muscular Dystrophy Association Announces Nearly $400K in Research Grants to Address Challenges in Duchenne Muscular Dystrophy Gene Therapy
13 mars 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, March 13, 2023 (GLOBE NEWSWIRE) -- Today, Muscular Dystrophy Association (MDA) announced two research grants designed to address potential transgene-triggered safety concerns in...
Muscular Dystrophy Association’s Venture Philanthropy Program Announces Investment in Non-viral Gene Therapy
25 janv. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announces a $650,000 investment in Myosana Therapeutics via its MDA Venture Philanthropy (MVP) program....